SETD1A and schizophrenia: This suggests that both these anti-psychotic agents are ineffective for ameliorating schizophrenia-relevant phenotypes in Setd1a+/- mice, of both sexes, and point to deficits in neural systems other than the monoamine system which may be consistent with variable responses to antipsychotic treatment in individuals with SETD1A variant-associated schizophrenia [16].